APO RESEARCH · REPORT
Covid-19 Vaccine
A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
Product & engineering
Understand the product.
A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.
The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.
Selected research
Industry Growth & Trends
Global Covid-19 Vaccine Industry Growth and Trends Forecast to 2032
Market perspective
A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.
The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.
Read the full market overview
According to APO Research, the global Covid-19 Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
This report provides a structured, data-driven view of the global Covid-19 Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Covid-19 Vaccine market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Covid-19 Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Covid-19 Vaccine.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Covid-19 Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Covid-19 Vaccine Market by Company
Moderna
CanSino Biologicals
Inovio Pharmaceuticals
Shenzhen Geno-Immune Medical Institute
GlaxoSmithKine
Pfizer
Johnson＆Johnson
Heat Biologics
Sanofi
Covid-19 Vaccine Segment by Type
DNA
Non-replicating Viral Vector
Protein Subunit
RNA
Others
Covid-19 Vaccine Segment by Application
Adults
Children
Covid-19 Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Covid-19 Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Covid-19 Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Covid-19 Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Covid-19 Vaccine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- DNA
- Non-replicating Viral Vector
- Protein Subunit
- RNA
- Others
Applications
- Adults
- Children
Companies covered
- Moderna
- CanSino Biologicals
- Inovio Pharmaceuticals
- Shenzhen Geno-Immune Medical Institute
- GlaxoSmithKine
- Pfizer
- Johnson＆Johnson
- Heat Biologics
- Sanofi
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Covid-19 Vaccine Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Covid-19 Vaccine Market Size by Region (2021-2032)
- 1.4.1 Global Covid-19 Vaccine Market Size by Region (2021-2026)
- 1.4.2 Global Covid-19 Vaccine Market Size by Region (2027-2032)
- 1.5 Key Regions Covid-19 Vaccine Market Size (2021-2032)
- 1.5.1 North America Covid-19 Vaccine Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Covid-19 Vaccine Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Covid-19 Vaccine Market Size Growth Rate (2021-2032)
- 1.5.4 South America Covid-19 Vaccine Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Covid-19 Vaccine Market Size Growth Rate (2021-2032)
2 Covid-19 Vaccine Market by Type
- 2.1 Type Introduction
- 2.1.1 DNA
- 2.1.2 Non-replicating Viral Vector
- 2.1.3 Protein Subunit
- 2.1.4 RNA
- 2.1.5 Others
- 2.2 Global Covid-19 Vaccine Market Size by Type
- 2.2.1 Global Covid-19 Vaccine Market Size Overview by Type (2021-2032)
- 2.2.2 Global Covid-19 Vaccine Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Covid-19 Vaccine Market Size Forecasted by Type (2027-2032)
- 2.3 Global Covid-19 Vaccine Market Size by Regions
- 2.3.1 North America Covid-19 Vaccine Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Covid-19 Vaccine Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Covid-19 Vaccine Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Covid-19 Vaccine Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Covid-19 Vaccine Market Size Breakdown by Type (2021-2026)
3 Covid-19 Vaccine Market by Application
- 3.1 Type Introduction
- 3.1.1 Adults
- 3.1.2 Children
- 3.2 Global Covid-19 Vaccine Market Size by Application
- 3.2.1 Global Covid-19 Vaccine Market Size Overview by Application (2021-2032)
- 3.2.2 Global Covid-19 Vaccine Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Covid-19 Vaccine Market Size Forecasted by Application (2027-2032)
- 3.3 Global Covid-19 Vaccine Market Size by Regions
- 3.3.1 North America Covid-19 Vaccine Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Covid-19 Vaccine Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Covid-19 Vaccine Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Covid-19 Vaccine Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Covid-19 Vaccine Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Covid-19 Vaccine Industry Trends
- 4.2 Covid-19 Vaccine Industry Drivers
- 4.3 Covid-19 Vaccine Industry Opportunities and Challenges
- 4.4 Covid-19 Vaccine Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Covid-19 Vaccine Revenue (2021-2026)
- 5.2 Global Covid-19 Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Covid-19 Vaccine Key Company Headquarters & Area Served
- 5.4 Global Covid-19 Vaccine Company, Product Type & Application
- 5.5 Global Covid-19 Vaccine Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Covid-19 Vaccine Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Covid-19 Vaccine Players Market Share by Revenue in 2025
- 5.6.3 2025 Covid-19 Vaccine Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Moderna
- 6.1.1 Moderna Company Information
- 6.1.2 Moderna Business Overview
- 6.1.3 Moderna Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Moderna Covid-19 Vaccine Product Portfolio
- 6.1.5 Moderna Recent Developments
- 6.2 CanSino Biologicals
- 6.2.1 CanSino Biologicals Company Information
- 6.2.2 CanSino Biologicals Business Overview
- 6.2.3 CanSino Biologicals Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 CanSino Biologicals Covid-19 Vaccine Product Portfolio
- 6.2.5 CanSino Biologicals Recent Developments
- 6.3 Inovio Pharmaceuticals
- 6.3.1 Inovio Pharmaceuticals Company Information
- 6.3.2 Inovio Pharmaceuticals Business Overview
- 6.3.3 Inovio Pharmaceuticals Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Inovio Pharmaceuticals Covid-19 Vaccine Product Portfolio
- 6.3.5 Inovio Pharmaceuticals Recent Developments
- 6.4 Shenzhen Geno-Immune Medical Institute
- 6.4.1 Shenzhen Geno-Immune Medical Institute Company Information
- 6.4.2 Shenzhen Geno-Immune Medical Institute Business Overview
- 6.4.3 Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Shenzhen Geno-Immune Medical Institute Covid-19 Vaccine Product Portfolio
- 6.4.5 Shenzhen Geno-Immune Medical Institute Recent Developments
- 6.5 GlaxoSmithKine
- 6.5.1 GlaxoSmithKine Company Information
- 6.5.2 GlaxoSmithKine Business Overview
- 6.5.3 GlaxoSmithKine Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 GlaxoSmithKine Covid-19 Vaccine Product Portfolio
- 6.5.5 GlaxoSmithKine Recent Developments
- 6.6 Pfizer
- 6.6.1 Pfizer Company Information
- 6.6.2 Pfizer Business Overview
- 6.6.3 Pfizer Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Pfizer Covid-19 Vaccine Product Portfolio
- 6.6.5 Pfizer Recent Developments
- 6.7 Johnson＆Johnson
- 6.7.1 Johnson＆Johnson Company Information
- 6.7.2 Johnson＆Johnson Business Overview
- 6.7.3 Johnson＆Johnson Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Johnson＆Johnson Covid-19 Vaccine Product Portfolio
- 6.7.5 Johnson＆Johnson Recent Developments
- 6.8 Heat Biologics
- 6.8.1 Heat Biologics Company Information
- 6.8.2 Heat Biologics Business Overview
- 6.8.3 Heat Biologics Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Heat Biologics Covid-19 Vaccine Product Portfolio
- 6.8.5 Heat Biologics Recent Developments
- 6.9 Sanofi
- 6.9.1 Sanofi Company Information
- 6.9.2 Sanofi Business Overview
- 6.9.3 Sanofi Covid-19 Vaccine Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Sanofi Covid-19 Vaccine Product Portfolio
- 6.9.5 Sanofi Recent Developments
7 North America
- 7.1 North America Covid-19 Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Covid-19 Vaccine Market Size by Country (2021-2026)
- 7.3 North America Covid-19 Vaccine Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Covid-19 Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Covid-19 Vaccine Market Size by Country (2021-2026)
- 8.3 Europe Covid-19 Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Covid-19 Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Covid-19 Vaccine Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Covid-19 Vaccine Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Covid-19 Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Covid-19 Vaccine Market Size by Country (2021-2026)
- 10.3 South America Covid-19 Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Covid-19 Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Covid-19 Vaccine Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Covid-19 Vaccine Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst